Regenxbio Completes $100 Million Public Offering

Regenxbio has announced the completion of a $100 million public offering at $9 per share. The company plans to sell approximately 11.1 million shares in the offering. Proceeds from the offering are expected to be used for general corporate purposes. The offering price includes a discount relative to Regenxbio's last closing price. The company aims to increase liquidity and strengthen its balance sheet through this transaction. The offering is expected to close in the first quarter of 2025, subject to customary closing conditions. Regenxbio, a biotechnology firm focused on gene therapy, is notable for this offering, which aims to meet sector funding needs. Investors view the offering as contributing to the company's future R&D efforts. This is not investment advice.